KCM
CGON icon

Kynam Capital Management’s CG Oncology CGON Stock Holding History

Kynam Capital Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-945,830
Closed -$39.3M – 41
2025
Q4 		$39.3M Sell
945,830
-1,059,375
-53% -$43.8M 2.51% 10
2025
Q3 		$80.8M Sell
2,005,205
-452,462
-18% -$13.2M 6.01% 7
2025
Q2 		$63.9M Sell
2,457,667
-153,995
-6% -$3.71M 6.88% 6
2025
Q1 		$64M Buy
2,611,662
+91,957
+4% +$2.59M 5.37% 6
2024
Q4 		$72.3M Buy
2,519,705
+748,900
+42% +$25.6M 4.27% 7
2024
Q3 		$66.8M Buy
1,770,805
+1,716,894
+3,185% +$60.2M 5.12% 9
2024
Q2 		$1.7M Buy
+53,911
New +$1.87M 0.13% 26

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Kynam Capital Management's CGON Position: Q1 2026 in Review

Kynam Capital Management sold out of CG Oncology (CGON) in Q1 2026, closing a stake of 945,830 shares — an estimated $39.3M sold.

Kynam Capital Management first reported a position in CGON in Q2 2024 and held it in 7 quarters. The position peaked at $80.8M in Q3 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Kynam Capital Management reported no remaining CG Oncology position as of Q1 2026 after selling out during the quarter.
  • Kynam Capital Management sold 945,830 CG Oncology shares in Q1 2026, an estimated $39.3M.
  • Kynam Capital Management first reported a position in CG Oncology in Q2 2024 and held it in 7 quarters.
  • Kynam Capital Management's CG Oncology position peaked at $80.8M in Q3 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.